{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors+and+Hematologic+Malignancy&page=16", "query": { "condition": "Solid Tumors and Hematologic Malignancy", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 573, "total_pages": 58, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors+and+Hematologic+Malignancy&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors+and+Hematologic+Malignancy&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:26:55.608Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00060645", "title": "Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "ridaforolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2003-05", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2015-08-27", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060645" }, { "nct_id": "NCT03061305", "title": "Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Adult Solid Tumor", "Lymphoma", "Multiple Myeloma" ], "interventions": [], "intervention_types": [], "sponsor": "Strata Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58213, "start_date": "2016-11", "completion_date": "2024-06-27", "has_results": false, "last_update_posted_date": "2025-01-31", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Pasadena, California • Vallejo, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pasadena", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Broomfield", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03061305" }, { "nct_id": "NCT00062881", "title": "Intrathecal Mafosfamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Meningeal Neoplasms" ], "interventions": [ { "name": "Intrathecal Mafosfamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 65, "start_date": "1990-06", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 10, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062881" }, { "nct_id": "NCT00589381", "title": "Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fenretinide lipid matrix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-08", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 4, "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • Bethesda, Maryland", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589381" }, { "nct_id": "NCT00019656", "title": "Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "perifosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019656" }, { "nct_id": "NCT00580034", "title": "Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Myeloma", "Leukemia", "Myelodysplasia", "Solid Tumors" ], "interventions": [ { "name": "Campath Purged Non-myeloablative ASCT", "type": "DRUG" }, { "name": "Donor Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "David Rizzieri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 176, "start_date": "2003-02", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-06-03", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580034" }, { "nct_id": "NCT06385483", "title": "Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2018-02-28", "completion_date": "2027-01-15", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385483" }, { "nct_id": "NCT05101213", "title": "Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenovirus Infection", "BK Virus Infection", "Cytomegaloviral Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "JC Virus Infection", "Malignant Solid Neoplasm", "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Virus-specific Cytotoxic T-lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-01-06", "completion_date": "2026-08-03", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05101213" }, { "nct_id": "NCT03997968", "title": "A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignancy", "Non-hodgkin Lymphoma", "Multiple Myeloma", "Breast Cancer", "Ovarian Cancer", "Soft Tissue Sarcoma", "Head and Neck Cancer", "DLBCL", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Pancreatic Cancer", "CLL", "Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "CYT-0851", "type": "DRUG" }, { "name": "CYT-0851 in combination with gemcitabine", "type": "DRUG" }, { "name": "CYT-0851 in combination with capecitabine", "type": "DRUG" }, { "name": "CYT-0851 in combination with rituximab and bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cyteir Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-10-09", "completion_date": "2024-12-20", "has_results": false, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 16, "location_summary": "San Francisco, California • Stanford, California • Denver, Colorado + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03997968" }, { "nct_id": "NCT07071909", "title": "Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignancy", "Cancer", "Hematological Malignancies", "Lymphoma", "Leukemia", "Multiple Myeloma", "Solid Tumor" ], "interventions": [ { "name": "Commercial CAR-T", "type": "BIOLOGICAL" }, { "name": "Investigational CAR-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2025-01-20", "completion_date": "2025-08-29", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-10-15T00:26:55.608Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07071909" } ] }